...
首页> 外文期刊>Breast Cancer Research >The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells
【24h】

The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells

机译:相对于匹配的原发肿瘤,膜粘蛋白MUC4在乳腺肿瘤淋巴结转移中升高,并赋予乳腺癌细胞侵袭性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

IntroductionPrevious studies indicate that overexpression of the membrane-associated mucin MUC4 is potently anti-adhesive to cultured tumor cells, and suppresses cellular apoptotic response to a variety of insults. Such observations raise the possibility that MUC4 expression could contribute to tumor progression or metastasis, but the potential involvement of MUC4 in breast cancer has not been rigorously assessed. The present study aimed to investigate the expression of the membrane mucin MUC4 in normal breast tissue, primary breast tumors and lymph node metastases, and to evaluate the role of MUC4 in promoting the malignant properties of breast tumor cells.MethodsMUC4 expression levels in patient-matched normal and tumor breast tissue was initially examined by immunoblotting lysates of fresh frozen tissue samples with a highly specific preparation of anti-MUC4 monoclonal antibody 1G8. Immunohistochemical analysis was then carried out using tissue microarrays encompassing patient-matched normal breast tissue and primary tumors, and patient-matched lymph node metastases and primary tumors. Finally, shRNA-mediated knockdown was employed to assess the contribution of MUC4 to the cellular growth and malignancy properties of JIMT-1 breast cancer cells.ResultsImmunoblotting and immunohistochemistry revealed that MUC4 levels are suppressed in the majority (58%, p < 0.001) of primary tumors relative to patient-matched normal tissue. On the other hand, lymph node metastatic lesions from 37% (p < 0.05) of patients expressed higher MUC4 protein levels than patient-matched primary tumors. MUC4-positive tumor emboli were often found in lymphovascular spaces of lymph node metastatic lesions. shRNA-mediated MUC4 knockdown compromised the migration, proliferation and anoikis resistance of JIMT-1 cells, strongly suggesting that MUC4 expression actively contributes to cellular properties associated with breast tumor metastasis.ConclusionsOur observations suggest that after an initial loss of MUC4 levels during the transition of normal breast tissue to primary tumor, the re-establishment of elevated MUC4 levels confers an advantage to metastasizing breast tumor cells by promoting the acquisition of cellular properties associated with malignancy.
机译:引言先前的研究表明,膜相关粘蛋白MUC4的过度表达对培养的肿瘤细胞具有强抗粘附力,并抑制细胞对多种损伤的凋亡反应。这些观察结果增加了MUC4表达可能有助于肿瘤进展或转移的可能性,但是尚未严格评估MUC4在乳腺癌中的潜在作用。本研究旨在探讨膜粘蛋白MUC4在正常乳腺组织,原发性乳腺肿瘤和淋巴结转移中的表达,并评估MUC4在促进乳腺肿瘤细胞恶性特性中的作用。通过免疫印迹新鲜冷冻的组织样品的裂解物并用高度特异性的抗MUC4单克隆抗体1G8进行免疫印迹检查,初步检查了正常和肿瘤的乳腺组织。然后使用包括患者匹配的正常乳腺组织和原发性肿瘤,以及患者匹配的淋巴结转移和原发性肿瘤在内的组织微阵列进行免疫组织化学分析。最后,shRNA介导的敲低被用来评估MUC4对JIMT-1乳腺癌细胞生长和恶性特性的贡献。结果免疫印迹和免疫组化显示,MUC4的水平在大多数(58%,p <0.001)中被抑制。相对于患者匹配的正常组织的原发性肿瘤。另一方面,来自患者的37%(p <0.05)的淋巴结转移性病变表达的MUC4蛋白水平高于患者匹配的原发性肿瘤。在淋巴结转移性病变的淋巴血管间隙常发现MUC4阳性的肿瘤栓子。 shRNA介导的MUC4敲低损害了JIMT-1细胞的迁移,增殖和抗厌食症,强烈表明MUC4的表达积极促进了与乳腺癌转移相关的细胞特性。对于正常的乳腺组织到原发肿瘤,升高的MUC4水平的重建可通过促进与恶性肿瘤相关的细胞特性的获得而赋予转移乳腺肿瘤细胞的优势。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号